Acurx Pharmaceuticals, Inc.
ACXP
$3.10
$0.3211.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.53% | -30.81% | -31.47% | -21.39% | 2.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.89% | -43.79% | -39.99% | -25.92% | -3.13% |
| Operating Income | 42.89% | 43.79% | 39.99% | 25.92% | 3.13% |
| Income Before Tax | 43.51% | 44.21% | 40.23% | 26.03% | 3.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.51% | 44.21% | 40.23% | 26.03% | 3.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.51% | 44.21% | 40.23% | 26.03% | 3.26% |
| EBIT | 42.89% | 43.79% | 39.99% | 25.92% | 3.13% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 66.00% | 60.64% | 53.29% | 40.03% | 22.87% |
| Normalized Basic EPS | 66.00% | 60.64% | 53.29% | 40.03% | 22.87% |
| EPS Diluted | 66.00% | 60.64% | 53.29% | 40.03% | 22.87% |
| Normalized Diluted EPS | 66.00% | 60.64% | 53.29% | 40.03% | 22.87% |
| Average Basic Shares Outstanding | 85.37% | 51.69% | 32.67% | 26.88% | 27.47% |
| Average Diluted Shares Outstanding | 85.37% | 51.69% | 32.67% | 26.88% | 27.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |